Trustmark National Bank Trust Department’s Vertex Pharmaceuticals VRTX Stock Holding History

Trustmark National Bank Trust Department's VRTX Position: Q1 2026 in Review

Trustmark National Bank Trust Department reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, selling an estimated $268K and leaving 4,189 shares worth $1.87M. The position accounts for 0.12% of the portfolio, ranked #123.

Trustmark National Bank Trust Department first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.01M in Q3 2024. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

• Trustmark National Bank Trust Department held 4,189 shares of Vertex Pharmaceuticals worth $1.87M as of Q1 2026.
• Trustmark National Bank Trust Department sold 574 Vertex Pharmaceuticals shares in Q1 2026, an estimated $268K.
• Vertex Pharmaceuticals made up 0.12% of Trustmark National Bank Trust Department's portfolio in Q1 2026, its #123 holding.
• Trustmark National Bank Trust Department first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
• Trustmark National Bank Trust Department's Vertex Pharmaceuticals position peaked at $3.01M in Q3 2024.
• 1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Trustmark National Bank Trust Department's 13F filing for Q1 2026, filed 14 May 2026.